A team of University of Zurich researchers led by Dr. Franz Vollenweider explored whether brain function under the influence of psilocybin was consistent with the brain function of chronic schizophrenia patients, finding that these brain states were significantly contrasted. They also found that psilocybin increased cerebral glucose metabolism (in layman’s terms brain activity) in many areas, and had dampening effects on the ego-influenced Default Mode Network. 

Studies and early-phase clinical trials already concluded at John Hopkins University, The Multidisciplinary Association for Psychedelic Studies (MAPS), The Beckley Foundation, Yale, Stanford, Berkeley, New York University, and more have shown Psychedelics to be both safe and efficient in treating a host of psychological conditions. Some of these conditions include depression, addiction, anxiety, OCD, PTSD, and eating disorders.​

In the decades since the turn of the century public attitude has also positively shifted towards the unfettered and open-minded research of psilocybin. Now, in 2020, governing bodies are beginning to follow suit. The FDA (Federal Drug Administration) has designated psilocybin a breakthrough therapy for Major Depressive Disorder (MDD), and Health Canada has granted several licenses to private and public companies in order to study psychedelics, most prominently psilocybin. ​

Over a dozen accredited institutions, a few of which include Harvard, Stanford, Yale, The Usona Institute, The Heffter Institute, Johns Hopkins University, and the University of Toronto are in the process of clinical trials/studies to determine the potential of psilocybin as a therapeutic aid, and there is a mountain of anecdotal evidence that cannot be discounted.